O-phosphoserine sulfhydrylase variant and method for producing cysteine using same

The O-phosphoserine sulfhydrylase variant, with specific amino acid modifications, improves cysteine production yield in microorganisms, addressing the limitations of existing methods by enhancing conversion activity and production levels.

WO2024248498A1PCT designated stage expired Publication Date: 2024-12-05CJ CHEILJEDANG CORP
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/007386
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-01
Filing Date
2024-05-30
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Existing methods for producing L-cysteine, such as direct fermentation using E. coli and conversion of O-phosphoserine, require excessive precursor production and have limitations in yield.

Method used

Development of an O-phosphoserine sulfhydrylase variant with 0 to 7 amino acid residues deleted from the C-terminus and the 77th position amino acid replaced with alanine, which is used in microorganisms to enhance cysteine production yield.

Benefits of technology

The O-phosphoserine sulfhydrylase variant achieves a higher yield of cysteine compared to microorganisms with wild-type O-phosphoserine sulfhydrylase, as demonstrated by increased cysteine conversion activity and production levels.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024007386_05122024_PF_FP_ABST
    Figure KR2024007386_05122024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to an O-phosphoserine sulfhydrylase variant and a method for producing cysteine using same.
Need to check novelty before this filing date? Find Prior Art

Description

O-phosphoserine sulfhydrylase mutant and method for producing cysteine ​​using the same

[0001] The present application relates to an O-phosphoserine sulfhydrylase variant and a method for producing cysteine ​​using the same.

[0002]

[0003] L-cysteine ​​is an important amino acid in sulfur metabolism in all living organisms, and is used in the synthesis of proteins in the body, such as keratin in hair, glutathione, biotin, methionine, and other sulfur-containing metabolites, as well as a precursor for coenzyme A biosynthesis.

[0004] Known methods for producing L-cysteine ​​using microorganisms include 1) a method for biologically converting D,L-ATC (D,L-2-amino-2-thiazoline-4-carboxylate) using microorganisms, 2) a direct fermentation method for producing L-cysteine ​​using E. coli (European Patent EP0885962B), and 3) a method for fermenting and producing O-phosphoserine (hereinafter "OPS") using microorganisms and then converting it into L-cysteine ​​by reacting it with sulfide under the catalytic action of O-phosphoserine sulfhydrylase (hereinafter "OPSS") (US 2012-0190080 A1).

[0005] At this time, in order to produce high yield cysteine ​​using the above method 3), there was a need to produce an excessive amount of OPS, which is a precursor.

[0006]

[0007] The present inventors completed the present application by confirming that when the O-phosphoserine sulfhydrylase variant of the present application is used in a microorganism producing cysteine, high yield cysteine ​​production is possible compared to a microorganism having an existing wild-type O-phosphoserine sulfhydrylase.

[0008]

[0009] The present application provides an O-phosphoserine sulfhydrylase variant in which 0 to 7 amino acid residues from the C-terminus of the amino acid sequence of SEQ ID NO: 1 are deleted and the amino acid corresponding to position 77 is substituted with alanine.

[0010] The present application provides a polynucleotide encoding an O-phosphoserine sulfhydrylase variant of the present application.

[0011] The present application provides a microorganism comprising an O-phosphoserine sulfhydrylase variant of the present application; or a polynucleotide encoding the same.

[0012] The present application provides a method for producing cysteine ​​or a derivative thereof, comprising the step of reacting a mixture of O-phosphoserine of the present application and a sulfide with an O-phosphoserine sulfhydrylase variant of the present application.

[0013]

[0014] When a microorganism producing cysteine ​​is cultured using the O-phosphoserine sulfhydrylase mutant of the present application, high yields of cysteine ​​can be produced compared to a microorganism having a wild-type O-phosphoserine sulfhydrylase.

[0015]

[0016] Figure 1 is a diagram showing the CysM mutants K12 / pUC_Ppro-cysM(P77S) (Msm-T-HA2) and K12 / pUC_Ppro-cysM(P77A) confirmed through SDS-PAGE.

[0017]

[0018] This is explained in detail as follows. Meanwhile, each description and embodiment disclosed in this application can also be applied to each other description and embodiment. That is, all combinations of the various elements disclosed in this application fall within the scope of this application. Furthermore, the scope of this application is not limited by the specific descriptions described below. Furthermore, numerous papers and patent documents are referenced and cited throughout this specification. The disclosures of the cited papers and patent documents are incorporated into this specification in their entirety by reference to more clearly explain the level of the technical field to which this application belongs and the contents of this application.

[0019]

[0020] One aspect of the present application provides an O-phosphoserine sulfhydrylase variant in which 0 to 7 amino acid residues from the C-terminus of the amino acid sequence of SEQ ID NO: 1 are deleted and the amino acid corresponding to position 77 is substituted with alanine.

[0021]

[0022] In this application, the term "O-phosphoserine sulfhydrylase (OPSS)" refers to an enzyme that catalyzes a reaction that converts OPS into cysteine ​​by providing a thiol group (SH group) to the OPS. The enzyme may have been first discovered in Aeropymm pernix, Mycobacterium tuberculosis, Mycobacterium smegmatics, and Trichomonas vaginalis (Mino K and Ishikawa K, FEBSletters, 551:133-138, 2003; Bums KE et al., J. Am. Chem. Soc, 127: 11602-11603, 2005).

[0023] The O-phosphoserine sulfhydrylase of the present application may include any polypeptide having O-phosphoserine sulfhydrylase activity or all O-phosphoserine sulfhydrylases. The O-phosphoserine sulfhydrylase or all O-phosphoserine sulfhydrylases may include any polypeptide having O-phosphoserine sulfhydrylase activity or an activity that converts O-phosphoserine (OPS) as a substrate into cysteine. For example, the O-phosphoserine sulfhydrylase of the present application may be any polypeptide having O-phosphoserine sulfhydrylase activity derived from a microorganism or an activity that converts OPS as a substrate into cysteine. Specifically, any polypeptide having O-phosphoserine sulfhydrylase activity of the present application may be derived from a prokaryotic microorganism or a eukaryotic microorganism, and more specifically, may be derived from a microorganism of the genus Mycobacterium, but is not limited thereto. As another example, any polypeptide having O-phosphoserine sulfhydrylase activity of the present application may be cysteine ​​synthase (CysM) derived from a microorganism of the genus Mycobacterium. The amino acid sequence of CysM can be obtained from a known database such as NCBI's Genebank. As an example, it may be WP_003896302.1 derived from a microorganism of the genus Mycobacterium, but it is obvious that it includes proteins having O-phosphoserine sulfhydrylase activity or an activity of converting OPS as a substrate into cysteine ​​of various origins.

[0024] In addition, the O-phosphoserine sulfhydrylase of the present application includes not only a wild-type O-phosphoserine sulfhydrylase protein, but also a mutant protein having a sequence in which a part of the polynucleotide sequence encoding the O-phosphoserine sulfhydrylase is deleted, substituted, or added, and exhibits an activity equivalent to or higher than the biological activity of the wild-type O-phosphoserine sulfhydrylase protein, and may also include all of the O-phosphoserine sulfhydrylase proteins disclosed in EP 2444481 A1 and US 2012-0190080 A and mutant proteins thereof.

[0025] The above “O-phosphoserine sulfhydrylase” may also be referred to as “OPSS”, “cysteine ​​synthetase”, “CysM”, etc.

[0026]

[0027] In the present application, the term "O-phosphoserine sulfhydrylase (OPSS) variant" means any polypeptide having O-phosphoserine sulfhydrylase activity or a variant comprising a deletion of 0 to 7 amino acid residues from the C-terminus of the amino acid sequence of SEQ ID NO: 1 and a substitution of an amino acid corresponding to the 77th position from the N-terminus of SEQ ID NO: 1 with alanine.

[0028] The above "O-phosphoserine sulfhydrylase variant" may also be referred to as "mutant O-phosphoserine sulfhydrylase", "OPSS variant", "mutant OPSS", "CysM variant", "mutant CysM", etc.

[0029] The protein to be subjected to mutation in the present application may be a protein having O-phosphoserine sulfhydrylase activity or an activity that converts OPS as a substrate into cysteine. Specifically, the protein may have the amino acid sequence of SEQ ID NO: 1 and may have O-phosphoserine sulfhydrylase activity or an activity that converts OPS as a substrate into cysteine, but is not limited thereto. This does not exclude meaningless sequence additions before or after the amino acid sequence of SEQ ID NO: 1, mutations that may occur naturally, or silent mutations thereof, and if it has the same or corresponding activity as the protein including the amino acid sequence of SEQ ID NO: 1, it may be a protein to be subjected to mutation in the present application. For example, the protein that is the target of mutation introduction in the present application may be a protein composed of an amino acid sequence of SEQ ID NO: 1 or an amino acid sequence that has 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or more homology or identity thereto. In addition, it is obvious that a protein that has an amino acid sequence in which part of the sequence is deleted, modified, substituted, or added is also included within the scope of the protein that is the target of mutation in the present application, as long as it is an amino acid sequence that has such homology or identity and exhibits an effect corresponding to the protein. An example of a sequence that can be the protein that is the target of mutation in the present application, i.e., the parent sequence, may be the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 13.

[0030]

[0031] The O-phosphoserine sulfhydrylase variant of the present application may have 0 to 7 amino acid residues deleted from the C-terminus in the amino acid sequence of SEQ ID NO: 1, and an amino acid at a position corresponding to the 77th position from the N-terminus in the amino acid sequence of SEQ ID NO: 1 may be substituted with an amino acid different from the amino acid before substitution. Specifically, the O-phosphoserine sulfhydrylase variant of the present application may have 3 to 7 amino acid residues deleted from the C-terminus in the amino acid sequence of SEQ ID NO: 1, and an amino acid at a position corresponding to the 77th position from the N-terminus in the amino acid sequence of SEQ ID NO: 1 may be substituted with an amino acid different from the amino acid before substitution. More specifically, the O-phosphoserine sulfhydrylase variant of the present application may have 5 amino acid residues deleted from the C-terminus in the amino acid sequence of SEQ ID NO: 1, and an amino acid at a position corresponding to the 77th position from the N-terminus in the amino acid sequence of SEQ ID NO: 1 may be substituted with an amino acid different from the amino acid before substitution. In the present application, the amino acid before substitution corresponding to position 77 of SEQ ID NO: 1 in the amino acid sequence before substitution of the O-phosphoserine sulfhydrylase protein that is the target of mutation introduction may be proline (P).

[0032] For example, the O-phosphoserine sulfhydrylase variant may be one in which the amino acid corresponding to position 77 in the amino acid sequence of SEQ ID NO: 1 is substituted with an amino acid other than proline. As another example, the O-phosphoserine sulfhydrylase variant may be one in which the amino acid corresponding to position 77 in the amino acid sequence of SEQ ID NO: 1 is substituted with an amino acid selected from the group consisting of alanine, tyrosine, arginine, lysine, aspartic acid, asparagine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, threonine, cysteine, histidine, glycine, glutamic acid, and glutamine, and for example, may be substituted with alanine. Such amino acid substitutions may generally occur based on similarities in polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathic nature of the residues. For example, positively charged (basic) amino acids include arginine, lysine, and histidine; negatively charged (acidic) amino acids include glutamic acid and aspartic acid; aromatic amino acids include phenylalanine, tryptophan, and tyrosine; and hydrophobic amino acids include alanine, valine, isoleucine, leucine, methionine, phenylalanine, tyrosine, and tryptophan.

[0033] Additionally, amino acids can be classified into those with electrically charged side chains and those with uncharged side chains. Charged side chain amino acids include aspartic acid, glutamic acid, lysine, arginine, and histidine. Uncharged side chain amino acids can be further classified into nonpolar amino acids or polar amino acids. Nonpolar amino acids include glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, and proline. Polar amino acids include serine, threonine, cysteine, tyrosine, asparagine, and glutamine. Typically, conservative substitutions have little or no effect on the activity of a protein or polypeptide.

[0034]

[0035] In one embodiment, the O-phosphoserine sulfhydrylase variant of the present application may have, comprise, consist of, or consist essentially of the amino acid sequence set forth in SEQ ID NO: 3. The O-phosphoserine sulfhydrylase variant of the present application may comprise an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% homology or identity with the amino acid sequence of SEQ ID NO: 3. In addition, it is obvious that an O-phosphoserine sulfhydrylase variant having an amino acid sequence in which some of the sequences are deleted, modified, substituted, conservatively substituted or added is also included within the scope of the present application, provided that the amino acid sequence has such homology or identity and exhibits an effect corresponding to that of the O-phosphoserine sulfhydrylase variant of the present application.

[0036] For example, if the amino acid sequence has sequence additions or deletions, naturally occurring mutations, silent mutations or conservative substitutions that do not alter the function of the O-phosphoserine sulfhydrylase variant of the present application at the N-terminus, C-terminus and / or within the amino acid sequence.

[0037] The term "conservative substitution" refers to the replacement of one amino acid with another amino acid having similar structural and / or chemical properties. Such amino acid substitutions may generally be based on similarities in the polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathic nature of the residues. Typically, conservative substitutions may have little or no effect on the activity of a protein or polypeptide.

[0038]

[0039] The O-phosphoserine sulfhydrylase variant of the present application may further have an amino acid corresponding to a position selected from the group consisting of the 7th, 55th, 218th, and combinations thereof from the N-terminus in the amino acid sequence of SEQ ID NO: 1 substituted with an amino acid different from the amino acid before substitution.

[0040] In the amino acid sequence before substitution of the O-phosphoserine sulfhydrylase protein that is the target of mutation introduction in the present application, the amino acid before substitution corresponding to the 7th position of SEQ ID NO. 1 may be leucine (L), the amino acid before substitution corresponding to the 55th position may be alanine (A), and the amino acid before substitution corresponding to the 218th position may be alanine (A).

[0041] The O-phosphoserine sulfhydrylase variant of the present application may be, for example, one in which the amino acid corresponding to the 7th position in the amino acid sequence of SEQ ID NO: 1 is substituted with an amino acid other than leucine. As another example, the O-phosphoserine sulfhydrylase variant may be one in which the amino acid corresponding to the 7th position in the amino acid sequence of SEQ ID NO: 1 is substituted with an amino acid selected from the group consisting of proline, tyrosine, glycine, alanine, aspartic acid, glutamic acid, histidine, valine, lysine, arginine, isoleucine, methionine, phenylalanine, tryptophan, serine, threonine, cysteine, asparagine, and glutamine, and for example, it may be substituted with proline.

[0042] The O-phosphoserine sulfhydrylase variant of the present application may be, for example, one in which the amino acid corresponding to the 55th position in the amino acid sequence of SEQ ID NO: 1 is substituted with an amino acid other than alanine. As another example, the O-phosphoserine sulfhydrylase variant may be one in which the amino acid corresponding to the 55th position in the amino acid sequence of SEQ ID NO: 1 is substituted with an amino acid selected from the group consisting of valine, tyrosine, glycine, leucine, aspartic acid, glutamic acid, histidine, lysine, arginine, isoleucine, methionine, proline, phenylalanine, tryptophan, serine, threonine, cysteine, asparagine, and glutamine, and for example, the variant may be substituted with valine.

[0043] The O-phosphoserine sulfhydrylase variant of the present application may be, for example, one in which the amino acid corresponding to position 218 in the amino acid sequence of SEQ ID NO: 1 is substituted with an amino acid other than alanine. As another example, the O-phosphoserine sulfhydrylase variant may be one in which the amino acid corresponding to position 218 in the amino acid sequence of SEQ ID NO: 1 is substituted with an amino acid selected from the group consisting of glycine, tyrosine, leucine, aspartic acid, glutamic acid, histidine, valine, lysine, arginine, isoleucine, methionine, proline, phenylalanine, tryptophan, serine, threonine, cysteine, asparagine, and glutamine, and for example, may be substituted with glycine.

[0044] In one embodiment, the O-phosphoserine sulfhydrylase variant of the present application may have a deletion of 0 to 7, for example 3 to 7, amino acid residues from the C-terminus in the amino acid sequence of SEQ ID NO: 1 described above, and may further include one or more, two or more, or all three amino acid substitutions at positions corresponding to the 77th amino acid residue from the N-terminus in the amino acid sequence of SEQ ID NO: 1, while the substitution of the amino acid at the position corresponding to the 7th, 55th, or 218th amino acid residue from the N-terminus in the amino acid sequence of SEQ ID NO: 1 is fixed.

[0045] In another embodiment, the O-phosphoserine sulfhydrylase variant of the present application may have, comprise, consist of, or consist essentially of any one or more amino acid sequences selected from the group consisting of SEQ ID NOs: 5, 7, and 9. The O-phosphoserine sulfhydrylase variant of the present application may comprise an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% homology or identity with the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 7 or SEQ ID NO: 9. In addition, it is obvious that an O-phosphoserine sulfhydrylase variant having an amino acid sequence in which some of the sequences are deleted, modified, substituted, conservatively substituted or added is also included within the scope of the present application, provided that the amino acid sequence has such homology or identity and exhibits an effect corresponding to that of the O-phosphoserine sulfhydrylase variant of the present application.

[0046]

[0047] As used herein, the term "variant protein" or "variant" refers to a polypeptide in which one or more amino acids are conservatively substituted and / or modified, thereby differing from the amino acid sequence of the variant before the mutation, but retaining functions or properties. Such variants can generally be identified by modifying one or more amino acids in the amino acid sequence of the polypeptide and evaluating the properties of the modified polypeptide. That is, the ability of the variant may be increased, unchanged, or decreased compared to the polypeptide before the mutation. Furthermore, some variants may include variants in which one or more portions, such as the N-terminal leader sequence or the transmembrane domain, are deleted. Other variants may include variants in which portions are deleted from the N- and / or C-terminus of the mature protein. The term "mutant protein" may be used interchangeably with terms such as mutant, modification, mutant polypeptide, mutant protein, mutation, and variant (in English, modification, modified polypeptide, modified protein, mutant, mutein, divergent, etc.), and is not limited thereto as long as the term is used in the meaning of mutation. For the purpose of the present application, the mutant of the present application may be a polypeptide in which 0 to 7 amino acid residues from the C-terminus in the amino acid sequence of SEQ ID NO: 1 are deleted, and the amino acid at the position corresponding to the 77th position from the N-terminus in the amino acid sequence of SEQ ID NO: 1 is substituted with an amino acid different from the amino acid before substitution.Specifically, the variant of the present application may be a polypeptide in which 5 amino acid residues from the C-terminus in the amino acid sequence of SEQ ID NO: 1 are deleted, and the amino acid at the position corresponding to the 77th position from the N-terminus in the amino acid sequence of SEQ ID NO: 1 is replaced with an amino acid different from the amino acid before replacement. For example, the variant of the present application may be one in which the amino acid corresponding to the 77th position in the amino acid sequence of SEQ ID NO: 1 is replaced with an amino acid selected from the group consisting of alanine, tyrosine, arginine, lysine, aspartic acid, asparagine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, threonine, cysteine, histidine, glycine, glutamic acid, and glutamine, and for example, the variant may be replaced with alanine. Such amino acid substitutions may generally occur based on similarities in polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathic nature of the residues. For example, positively charged (basic) amino acids include arginine, lysine, and histidine; negatively charged (acidic) amino acids include glutamic acid and aspartic acid; aromatic amino acids include phenylalanine, tryptophan, and tyrosine; and hydrophobic amino acids include alanine, valine, isoleucine, leucine, methionine, phenylalanine, tyrosine, and tryptophan.

[0048] Additionally, amino acids can be classified into those with electrically charged side chains and those with uncharged side chains. Charged side chain amino acids include aspartic acid, glutamic acid, lysine, arginine, and histidine. Uncharged side chain amino acids can be further classified into nonpolar amino acids or polar amino acids. Nonpolar amino acids include glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, and proline. Polar amino acids include serine, threonine, cysteine, tyrosine, asparagine, and glutamine. Typically, conservative substitutions have little or no effect on the activity of a protein or polypeptide.

[0049] As another example, the variant of the present application may be, but is not limited to, a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 3.

[0050] The variant of the present application may be a polypeptide in which 5 amino acid residues from the C-terminus in the amino acid sequence of SEQ ID NO: 1 are deleted, and an amino acid at a position corresponding to the 77th position from the N-terminus in the amino acid sequence of SEQ ID NO: 1 is replaced with an amino acid different from the amino acid before substitution, and further, an amino acid corresponding to a position selected from the group consisting of the 7th, 55th, 218th positions from the N-terminus in the amino acid sequence of SEQ ID NO: 1 and combinations thereof is replaced with an amino acid different from the amino acid before substitution. For example, the variant of the present application may be one in which the amino acid corresponding to the 7th position in the amino acid sequence of SEQ ID NO: 1 is substituted with an amino acid selected from the group consisting of proline, tyrosine, glycine, alanine, aspartic acid, glutamic acid, histidine, valine, lysine, arginine, isoleucine, methionine, phenylalanine, tryptophan, serine, threonine, cysteine, asparagine, and glutamine, and for example, may be substituted with proline. The variant of the present application may be one in which the amino acid corresponding to the 55th position in the amino acid sequence of SEQ ID NO: 1 is substituted with an amino acid selected from the group consisting of valine, tyrosine, glycine, leucine, aspartic acid, glutamic acid, histidine, lysine, arginine, isoleucine, methionine, proline, phenylalanine, tryptophan, serine, threonine, cysteine, asparagine, and glutamine, and may be substituted with valine as an example. Alternatively, the variant of the present application may be one in which the amino acid corresponding to position 218 in the amino acid sequence of SEQ ID NO: 1 is substituted with an amino acid selected from the group consisting of glycine, tyrosine, leucine, aspartic acid, glutamic acid, histidine, valine, lysine, arginine, isoleucine, methionine, proline, phenylalanine, tryptophan, serine, threonine, cysteine, asparagine, and glutamine, and for example, may be substituted with glycine.As another example, the variant of the present application may be, but is not limited to, a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 5, SEQ ID NO: 7, or SEQ ID NO: 9. The variant may include the above-described modifications, and may have improved O-phosphoserine sulfhydrylase enzyme activity compared to a polypeptide in which the amino acid at the position corresponding to the 77th amino acid from the N-terminus in the amino acid sequence of SEQ ID NO: 1 is proline.

[0051] Additionally, variants may include deletions or additions of amino acids that have minimal impact on the properties and secondary structure of the polypeptide. For example, the N-terminus of the variant may be conjugated with a signal (or leader) sequence involved in co-translational or post-translational protein translocation. Furthermore, the variant may be conjugated to other sequences or linkers to facilitate identification, purification, or synthesis.

[0052]

[0053] In this application, the terms "homology" or "identity" refer to the degree of similarity between two given amino acid sequences or base sequences, which may be expressed as a percentage. The terms homology and identity are often used interchangeably.

[0054] Sequence homology or identity of conserved polynucleotides or polypeptides is determined by standard alignment algorithms, and may be combined with default gap penalties established by the program being used. In practice, homologous or identical sequences can generally hybridize with all or part of the sequence under moderate or high stringency conditions. It should be appreciated that hybridization also includes hybridization with polynucleotides containing common codons or codons that take codon degeneracy into account.

[0055] Whether any two polynucleotide or polypeptide sequences are homologous, similar or identical can be determined using known computer algorithms such as the "FASTA" program using default parameters, for example as in Pearson et al (1988) [Proc. Natl. Acad. Sci. USA 85]: 2444. Alternatively, the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the Needleman program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277) (version 5.0.0 or later) can be determined using the GCG program package (Devereux, J., et al, Nucleic Acids Research 12: 387 (1984)), BLASTP, BLASTN, FASTA (Atschul, [S.] [F.,] [ET AL, J MOLEC BIOL 215]: 403 (1990); Guide to Huge Computers, Martin J. Bishop, [ED.,] Academic Press, San Diego, 1994, and [CARILLO et al / .](1988) SIAM J Applied Math 48: 1073). For example, homology, similarity, or identity can be determined using BLAST or ClustalW from the National Center for Biotechnology Information database.

[0056] Homology, similarity, or identity of polynucleotides or polypeptides can be determined by comparing sequence information, for example, using a GAP computer program such as that of Needleman et al. (1970), J Mol Biol. 48:443, as disclosed, for example, in Smith and Waterman, Adv. Appl. Math (1981) 2:482. In brief, the GAP program can be defined as the total number of symbols in the shorter of the two sequences divided by the number of similarly arranged symbols (i.e., nucleotides or amino acids). Default parameters for the GAP program are (1) a unitary matrix (containing values ​​of 1 for identity and 0 for non-identity) and (2) a matrix of 1 and 0 for identity, as disclosed by Schwartz and Dayhoff, eds., Atlas Of Protein Sequence And Structure, National Biomedical Research Foundation, pp. 353-358 (1979), Gribskov et al. (1986) Nucl. Acids Res. 14: 6745 weighted comparison matrix (or EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix); (2) a penalty of 3.0 for each gap and an additional penalty of 0.10 for each symbol in each gap (or a gap opening penalty of 10 and a gap extension penalty of 0.5); and (3) no penalty for terminal gaps.

[0057]

[0058] The O-phosphoserine sulfhydrylase variant of the present invention may have increased cysteine ​​conversion activity compared to wild-type O-phosphoserine sulfhydrylase.

[0059] For example, the O-phosphoserine sulfhydrylase variant, which is the target enzyme for comparing whether the cysteine ​​conversion activity increases, may be, but is not limited to, Msm-T-HA2 (EP 2444486 B1).

[0060] For example, the variant of the present application with increased cysteine ​​conversion activity has an increase in cysteine ​​conversion activity of about 1% or more, specifically about 5% or more, about 10% or more, about 13% or more, about 15% or more, about 20% or more, about 25% or more, about 30% or more, about 35% or more, about 40% or more, about 41% or more, about 45% or more, about 46% or more, about 50% or more, about 55% or more, about 60% or more, about 65% or more, about 70% or more, about 72% or more, or about 72.5% or more (the upper limit is not particularly limited, and for example, about 200% or less, about 150% or less, about 100% or less, about 50% or less, about 40% or less, about 30% or less, about 20% or less, or about It may be increased by 15% or less), but is not limited thereto, as long as it has a positive value of increase compared to the cysteine ​​conversion activity of the enzyme before the mutation or the unmodified enzyme. In another example, the variant of the present application with increased cysteine ​​conversion activity has a cysteine ​​conversion activity of about 1.01 times or more, about 1.05 times or more, about 1.1 times or more, about 1.13 times or more, about 1.15 times or more, about 1.2 times or more, about 1.25 times or more, about 1.3 times or more, about 1.35 times or more, about 1.4 times or more, about 1.41 times or more, about 1.45 times or more, about 1.46 times or more, about 1.5 times or more, about 1.55 times or more, about 1.6 times or more, about 1.65 times or more, about 1.7 times or more, about 1.72 times or more, or about 1.725 times or more (the upper limit is not particularly limited, and for example, about 10 times or less, about 5 times or less, about 3 times or less, or It may be increased by, but is not limited to, approximately 2 times or less.

[0061] This cysteine ​​conversion ability can be evaluated by measuring the amount of cysteine ​​produced through the cysteine ​​conversion reaction. The evaluation can be performed by measuring the amount of cysteine ​​produced using a suitable method known in the art. For example, HPLC (High Performance Liquid Chromatography), GC (Gas Chromatography), GC / MS (Gas Chromatography-Mass Spectrometry), LC / MS (Liquid chromatography-mass spectrometry), GPC (Gel Permeation Chromatography) or a combination thereof can be used, and the amount of cysteine ​​produced can be measured using a suitable method known in the art.

[0062]

[0063] As used herein, the term "corresponding to" refers to an amino acid residue at a position listed in a polypeptide, or an amino acid residue that is similar, identical, or homologous to the residue listed in the polypeptide. Identifying an amino acid at a corresponding position may be determining a specific amino acid in a sequence that references a particular sequence. As used herein, "corresponding region" generally refers to a similar or corresponding position in a related or reference protein.

[0064] For example, any amino acid sequence can be aligned with SEQ ID NO: 1, and based on this, each amino acid residue of the amino acid sequence can be numbered by referring to the numerical position of the amino acid residue corresponding to the amino acid residue in SEQ ID NO: 1. For example, a sequence alignment algorithm such as that described in the present application can identify the position of an amino acid, or the position at which a modification such as a substitution, insertion, or deletion occurs, by comparing it to a query sequence (also referred to as a “reference sequence”).

[0065] For such alignment, for example, the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453), the Needleman program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000), Trends Genet. 16: 276-277) can be used, but is not limited thereto, and any sequence alignment program known in the art, pairwise sequence comparison algorithm, etc. can be appropriately used.

[0066]

[0067] Another aspect of the present application provides a polynucleotide encoding an O-phosphoserine sulfhydrylase variant of the present application.

[0068] The O-phosphoserine sulfhydrylase protein of the present application may be encoded by the cysM gene.

[0069] For example, the cysM gene may be a polynucleotide encoding WP_003896302.1 derived from a Mycobacterium genus microorganism, but is not limited thereto. In another example, the cysM gene may be a cysM gene derived from a Mycobacterium genus microorganism, but is not limited thereto, and it is apparent that the cysM gene includes genes of various origins encoding proteins having O-phosphoserine sulfhydrylase activity.

[0070] In this application, the term "polynucleotide" means a polymer of nucleotides in which nucleotide units (monomers) are covalently bonded to form a long chain, a DNA or RNA strand of a certain length or longer, and more specifically, a polynucleotide fragment encoding the O-phosphoserine sulfhydrylase variant.

[0071] The polynucleotide encoding the O-phosphoserine sulfhydrylase variant of the present application may include a base sequence encoding an O-phosphoserine sulfhydrylase variant in which 5 amino acid residues from the C-terminus of the amino acid sequence of SEQ ID NO: 1 are deleted, and the amino acid at the position corresponding to the 77th position from the N-terminus of the amino acid sequence of SEQ ID NO: 1 is substituted with another amino acid. For example, the polynucleotide of the present application may include a base sequence encoding the amino acid sequence set forth in SEQ ID NO: 3. In a more specific example of the present application, the polynucleotide of the present application may have or include the base sequence of SEQ ID NO: 4. In addition, the polynucleotide of the present application may consist of, or consist essentially of, the base sequence of SEQ ID NO: 4.

[0072] The polynucleotide of the present application may have various modifications made to the coding region within a range that does not change the amino acid sequence of the O-phosphoserine sulfhydrylase variant of the present application, taking into account the degeneracy of the codon or the codon preferred in the organism that is to express the O-phosphoserine sulfhydrylase variant of the present application. Specifically, the polynucleotide of the present application has or includes a base sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, and less than 100% homology or identity with the base sequence of SEQ ID NO: 4, or may consist of or consist essentially of a base sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, and less than 100% homology or identity with the base sequence of SEQ ID NO: 4, but is not limited thereto. At this time, in the sequence having the homology or identity, the codon encoding the amino acid corresponding to the 93rd position of SEQ ID NO: 1 may be one of the codons encoding an amino acid other than proline, for example, alanine.

[0073] In addition, the polynucleotide encoding the O-phosphoserine sulfhydrylase variant of the present application may further include a base sequence encoding an O-phosphoserine sulfhydrylase variant in which an amino acid corresponding to a position corresponding to the 77th position from the N-terminus in the amino acid sequence of SEQ ID NO: 1 is deleted from the amino acid sequence of SEQ ID NO: 1 and an amino acid corresponding to a position selected from the group consisting of the 7th, 55th, 218th, and combinations thereof from the N-terminus in the amino acid sequence of SEQ ID NO: 1 is substituted with an amino acid different from the amino acid before substitution. As an example, the polynucleotide of the present application may include a base sequence encoding any one or more amino acid sequences selected from the group consisting of SEQ ID NOs: 5, 7, and 9. As a more specific example of the present application, the polynucleotide of the present application may have or include the base sequence of SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 10. In addition, the polynucleotide of the present application may consist of, or consist essentially of, the base sequence of SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 10.

[0074] Specifically, the polynucleotide of the present application may have or include a base sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, and less than 100% homology or identity with the base sequence of SEQ ID NO: 6 or SEQ ID NO: 8 or SEQ ID NO: 10, or may consist of or consist essentially of a base sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, and less than 100% homology or identity with the base sequence of SEQ ID NO: 6 or SEQ ID NO: 8 or SEQ ID NO: 10, but is not limited thereto. At this time, in the sequence having the above homology or identity, the codon encoding the amino acid corresponding to the 7th position of SEQ ID NO: 1 may be one of the codons encoding an amino acid other than leucine, for example, proline, the codon encoding the amino acid corresponding to the 55th position of SEQ ID NO: 1 may be one of the codons encoding an amino acid other than alanine, for example, valine, and the codon encoding the amino acid corresponding to the 218th position of SEQ ID NO: 1 may be one of the codons encoding an amino acid other than alanine, for example, glycine.

[0075]

[0076] In addition, the polynucleotide of the present application may include, without limitation, a probe that can be prepared from a known genetic sequence, for example, a sequence that can hybridize under stringent conditions with a complementary sequence to all or part of the polynucleotide sequence of the present application. The term "stringent conditions" refers to conditions that enable specific hybridization between polynucleotides. Such conditions are specifically described in the literature (see J. Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press, Cold Spring Harbor, New York, 1989; FM Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York, 9.50-9.51, 11.7-11.8). For example, conditions in which polynucleotides having high homology or identity hybridize with each other, polynucleotides having 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more homology or identity hybridize with each other, and polynucleotides having lower homology or identity do not hybridize with each other, or conditions in which washing is performed once, specifically twice or three times, at a salt concentration and temperature equivalent to 60°C, 1ХSSC, 0.1% SDS, specifically 60°C, 0.1ХSSC, 0.1% SDS, and more specifically 68°C, 0.1ХSSC, 0.1% SDS, which are washing conditions of typical southern hybridization, are performed.

[0077] Hybridization requires that two nucleic acids have complementary sequences, although mismatches between bases are possible depending on the stringency of hybridization. The term "complementary" is used to describe the relationship between nucleotide bases that can hybridize with each other. For example, in DNA, adenine is complementary to thymine, and cytosine is complementary to guanine. Therefore, the polynucleotides of the present application may also include isolated nucleic acid fragments that are complementary in their entirety, as well as substantially similar nucleic acid sequences.

[0078] Specifically, a polynucleotide having homology or identity with the polynucleotide of the present application can be detected using hybridization conditions including a hybridization step at a Tm value of 55°C and using the conditions described above. In addition, the Tm value may be, but is not limited to, 60°C, 63°C, or 65°C, and can be appropriately adjusted by a person skilled in the art depending on the purpose.

[0079] The appropriate stringency for hybridizing the polynucleotides depends on the length and degree of complementarity of the polynucleotides, variables which are well known in the art (e.g., J. Sambrook et al., supra).

[0080]

[0081] Another aspect of the present application provides a vector comprising the polynucleotide of the present application.

[0082] The above vector may be an expression vector for expressing the above polynucleotide in a host cell, but is not limited thereto.

[0083] The vector of the present application may comprise a DNA construct comprising a base sequence of a polynucleotide encoding a target polypeptide operably linked to a suitable expression control region (or expression control sequence) so as to enable expression of the target polypeptide in a suitable host. The expression control region may comprise a promoter capable of initiating transcription, an optional operator sequence for regulating such transcription, a sequence encoding a suitable mRNA ribosome binding site, and sequences regulating the termination of transcription and translation. The vector may be capable of replicating or functioning independently of the host genome after being transformed into a suitable host cell, or may be integrated into the genome itself.

[0084] The vector used in the present application is not particularly limited, and any vector known in the art can be used. Examples of commonly used vectors include plasmids, cosmids, viruses, and bacteriophages in a natural or recombinant state. For example, pWE15, M13, MBL3, MBL4, IXII, ASHII, APII, t10, t11, Charon4A, and Charon21A can be used as phage vectors or cosmid vectors, and pDZ series, pBR series, pUC series, pBluescriptII series, pGEM series, pTZ series, pCL series, and pET series can be used as plasmid vectors. Specifically, pUC, pDZ, pDC, pDCM2, pACYC177, pACYC184, pCL, pECCG117, pUC19, pBR322, pMW118, pCC1BAC vectors can be used.

[0085] For example, a polynucleotide encoding a target polypeptide can be inserted into a chromosome via a vector for intracellular chromosomal insertion. The insertion of the polynucleotide into the chromosome can be achieved by any method known in the art, for example, homologous recombination, but is not limited thereto. A selection marker for confirming the chromosomal insertion can be additionally included. The selection marker is used to select cells transformed with the vector, i.e., to confirm the insertion of the target nucleic acid molecule. Markers that confer a selectable phenotype, such as drug resistance, nutrient requirement, cytotoxic agent resistance, or expression of a surface polypeptide, can be used. In an environment treated with a selective agent, only cells expressing the selection marker survive or exhibit other phenotypic traits, so that transformed cells can be selected.

[0086] The term "transformation" in this application refers to introducing a vector containing a polynucleotide encoding a target polypeptide into a host cell or microorganism so that the polypeptide encoded by the polynucleotide can be expressed in the host cell. The transformed polynucleotide may be located within the chromosome of the host cell or located extrachromosomally, as long as it can be expressed in the host cell. In addition, the polynucleotide includes DNA and / or RNA encoding the target polypeptide. The polynucleotide may be introduced in any form as long as it can be introduced into the host cell and expressed. For example, the polynucleotide may be introduced into the host cell in the form of an expression cassette, which is a genetic construct containing all elements necessary for autonomous expression. The expression cassette may typically include a promoter, a transcription termination signal, a ribosome binding site, and a translation termination signal, all of which are operably linked to the polynucleotide. The above expression cassette may be in the form of a self-replicating expression vector. Furthermore, the polynucleotide may be introduced into a host cell in its own form and operably linked to a sequence necessary for expression in the host cell, but is not limited thereto.

[0087] Additionally, the term "operably linked" as used herein means that the polynucleotide sequence is functionally linked to a promoter sequence that initiates and mediates transcription of the polynucleotide encoding the O-phosphoserine sulfhydrylase variant of the present application.

[0088]

[0089] Another aspect of the present application provides a microorganism comprising an O-phosphoserine sulfhydrylase variant of the present application; or a polynucleotide encoding the same.

[0090] The strain of the present application may comprise an O-phosphoserine sulfhydrylase variant of the present application, a polynucleotide encoding the polypeptide, or a vector comprising the polynucleotide of the present application.

[0091] In this application, the term "microorganism (or strain)" includes both wild-type microorganisms and microorganisms that have undergone genetic modification naturally or artificially, and may be a microorganism that has a specific mechanism weakened or strengthened due to causes such as insertion of an external gene or enhanced or inactivated activity of an endogenous gene, and may be a microorganism that includes genetic modification for the production of a desired polypeptide, protein or product.

[0092] The strain of the present application may be a strain naturally capable of producing cysteine, or a microorganism in which cysteine ​​production ability has been conferred on a strain lacking cysteine ​​production ability. For example, the strain may be a microorganism in which cysteine ​​production ability has been increased by introducing the O-phosphoserine sulfhydrylase variant of the present application or a polynucleotide encoding the same, but is not limited thereto.

[0093] The strain of the present application may be a microorganism having increased cysteine ​​production ability compared to a parent strain or a wild-type Mycobacterium strain that does not include the variant of the present application. The microorganism may have improved cysteine ​​production ability by introducing the O-phosphoserine sulfhydrylase variant of the present application having increased cysteine ​​conversion activity compared to the wild-type O-phosphoserine sulfhydrylase or a polynucleotide encoding the same. Specifically, the strain of the present application may have increased cysteine ​​production ability compared to a Mycobacterium microorganism comprising the wild-type O-phosphoserine sulfhydrylase having the amino acid sequence of SEQ ID NO: 1 or a polynucleotide encoding the same.

[0094]

[0095] In this application, the term "unmodified microorganism" does not exclude a strain that contains a mutation that can occur naturally in a microorganism, and may refer to a wild-type strain or a natural strain itself, or a strain before its characteristics are changed by genetic mutation caused by natural or artificial factors. In addition, the term "unmodified O-phosphoserine sulfhydrylase microorganism" in this application may refer to a strain that is not introduced or before the O-phosphoserine sulfhydrylase variant described herein is introduced. The unmodified O-phosphoserine sulfhydrylase microorganism in this application does not exclude a strain that contains a modification of a protein or another gene other than a modification of the O-phosphoserine sulfhydrylase or a polynucleotide encoding the same.

[0096] In this application, the term “unmodified microorganism” may be used interchangeably with “pre-modified strain”, “pre-modified microorganism”, “unmodified strain”, “unmodified microorganism”, or “reference microorganism”.

[0097] The microorganism of the present application may be, but is not limited to, a microorganism comprising an O-phosphoserine sulfhydrylase variant or a polynucleotide encoding the same; or a microorganism genetically modified to include an O-phosphoserine sulfhydrylase variant or a polynucleotide encoding the same (e.g., a recombinant microorganism). The term "intrinsic activity" refers to the activity of a specific polypeptide originally possessed by a parent strain, wild type, or unmodified microorganism before a change in trait, when the trait is changed due to genetic mutation caused by natural or artificial factors. This may be used interchangeably with "activity before modification."

[0098]

[0099] The microorganism of the present application is not particularly limited in type as long as it can produce cysteine, and may be either a prokaryotic cell or a eukaryotic cell, but may specifically be a prokaryotic cell. For example, the microorganism may include a strain of a microorganism belonging to the genus Escherichia, the genus Erwinia, the genus Seratia, the genus Providencia, the genus Corynebacterium, and the genus Brevibacterium, and may specifically be a microorganism belonging to the genus Escherichia, and more specifically, Escherichia coli, but is not limited thereto.

[0100]

[0101] As another example of the present application, the recombinant microorganism of the present application may be a microorganism with enhanced cysteine ​​production ability by additionally enhancing the activity of a portion of a protein in the cysteine ​​biosynthesis pathway or by weakening the activity of a portion of a protein in the cysteine ​​degradation pathway.

[0102]

[0103] In this application, the term "enhancement" of the activity of a polypeptide means that the activity of the polypeptide is increased compared to the intrinsic activity. The term "enhancement" may be used interchangeably with terms such as activation, up-regulation, overexpression, and increase. Here, activation, enhancement, up-regulation, overexpression, and increase may all include exhibiting an activity that was not originally present, or exhibiting an activity that is enhanced compared to the intrinsic activity or the activity before modification. "Enhancement," "up-regulation," "overexpression," or "increase" of the activity of a polypeptide compared to the intrinsic activity means that the activity and / or concentration (expression amount) of a specific polypeptide is enhanced compared to the activity and / or concentration (expression amount) that the parent strain or unmodified microorganism originally had before the transformation.

[0104] The above enhancement can be achieved by introducing an exogenous polypeptide, or by enhancing the activity and / or concentration (expression level) of an endogenous polypeptide. Whether the activity of the polypeptide is enhanced can be determined by an increase in the level of activity, expression level, or amount of product excreted from the polypeptide.

[0105] Enhancement of the activity of the above polypeptide can be achieved by applying various methods well known in the art, and is not limited as long as the activity of the target polypeptide can be enhanced compared to that of the microorganism before modification. Specifically, it may be achieved by using genetic engineering and / or protein engineering, which are routine methods of molecular biology and are well known to those skilled in the art, but is not limited thereto (e.g., Sitnicka et al. Functional Analysis of Genes. Advances in Cell Biology. 2010, Vol. 2. 1-16, Sambrook et al. Molecular Cloning 2012, etc.).

[0106] Specifically, the enhancement of the activity of the polypeptide of the present application is

[0107] 1) Increase in the intracellular copy number of a polynucleotide encoding a polypeptide;

[0108] 2) Replacing the gene expression control region on the chromosome encoding the polypeptide with a highly active sequence;

[0109] 3) Modification of the base sequence encoding the initiation codon or 5'-UTR region of a gene transcript encoding a polypeptide;

[0110] 4) Modification of the amino acid sequence of the polypeptide so as to enhance polypeptide activity;

[0111] 5) Modification of the polynucleotide sequence encoding the polypeptide so as to enhance the activity of the polypeptide (e.g., modification of the polynucleotide sequence of the polypeptide gene so as to encode a polypeptide modified so as to enhance the activity of the polypeptide);

[0112] 6) Introduction of a foreign polypeptide exhibiting the activity of the polypeptide or a foreign polynucleotide encoding the same;

[0113] 7) Codon optimization of a polynucleotide encoding a polypeptide;

[0114] 8) Analyze the tertiary structure of the polypeptide to select the exposed portion and modify or chemically modify it;

[0115] 9) Control of cellular localization of proteins (polypeptides); or

[0116] 10) It may be a combination of two or more selected from 1) to 9), but is not particularly limited thereto.

[0117] More specifically,

[0118] The increase in the intracellular copy number of the polynucleotide encoding the polypeptide described above 1) may be achieved by introducing into the host cell a vector capable of replicating and functioning independently of the host, to which the polynucleotide encoding the polypeptide is operably linked. Alternatively, the polynucleotide encoding the polypeptide (protein) operably linked to an appropriate regulatory sequence may be achieved by introducing one copy or two or more copies into the chromosome of the host cell (microorganism). The introduction into the chromosome may be performed by introducing into the host cell (microorganism) a vector capable of inserting the polynucleotide into the chromosome of the host cell (microorganism), but is not limited thereto. The vector is as described above. The above regulatory sequence may be a natural sequence (same origin) or a foreign sequence (derived from another gene) or a mutant sequence thereof or another artificial sequence relative to the polynucleotide sequence being encoded, and may induce expression of the polynucleotide in a host cell (microorganism). As an example of an embodiment, the regulatory sequence of a gene (cysM) encoding an O-phosphoserine sulfhydrylase (OPSS) protein derived from Mycobacterium smegmatics of the present application may be, but is not limited to, a PcysK promoter.

[0119] 2) Replacing the gene expression control region (or expression control sequence) on the chromosome encoding the polypeptide with a sequence having strong activity may be, for example, a mutation in the sequence such as deletion, insertion, non-conservative or conservative substitution, or a combination thereof to further enhance the activity of the expression control region, or replacement with a sequence having stronger activity. The expression control region may include, but is not particularly limited to, a promoter, an operator sequence, a sequence encoding a ribosome binding site, and a sequence regulating the termination of transcription and translation. As an example, it may be, but is not limited to, replacing the original promoter with a strong promoter.

[0120] Examples of known strong promoters include, but are not limited to, the CJ1 to CJ7 promoters (US Patent No. US 7662943 B2), the lac promoter, the trp promoter, the trc promoter, the tac promoter, the lambda phage PR promoter, the PL promoter, the tet promoter, the gapA promoter, the SPL7 promoter, the SPL13 (sm3) promoter (US Patent No. US 10584338 B2), the O2 promoter (US Patent No. US 10273491 B2), the tkt promoter, and the yccA promoter.

[0121] The above 3) modification of the base sequence encoding the initiation codon or 5'-UTR region of the gene transcript encoding the polypeptide may be, for example, a substitution with a base sequence encoding another initiation codon having a higher polypeptide expression rate than the endogenous initiation codon, but is not limited thereto.

[0122] The modification of the amino acid sequence or polynucleotide sequence of the above 4) and 5) may be, but is not limited to, a mutation in the sequence by deletion, insertion, non-conservative or conservative substitution or a combination thereof in the amino acid sequence of the polypeptide or the polynucleotide sequence encoding the polypeptide to enhance the activity of the polypeptide, or replacement with an amino acid sequence or polynucleotide sequence improved to have stronger activity or an amino acid sequence or polynucleotide sequence improved to have increased activity. The replacement may be specifically performed by inserting the polynucleotide into a chromosome by homologous recombination, but is not limited thereto. The vector used at this time may additionally include a selection marker to confirm whether or not chromosomal insertion has occurred.

[0123] The introduction of the foreign polynucleotide exhibiting the activity of the polypeptide as described above 6) may be the introduction into the host cell of a foreign polynucleotide encoding a polypeptide exhibiting the same / similar activity as the polypeptide. The foreign polynucleotide is not limited in its origin or sequence as long as it exhibits the same / similar activity as the polypeptide. The method used for the introduction may be performed by a person skilled in the art by appropriately selecting a known transformation method, and the polypeptide may be produced by expressing the introduced polynucleotide in the host cell, thereby increasing its activity.

[0124] The above 7) codon optimization of a polynucleotide encoding a polypeptide may be codon optimization of an endogenous polynucleotide to increase transcription or translation within a host cell, or codon optimization of a foreign polynucleotide to achieve optimized transcription or translation within a host cell.

[0125] The above 8) analyzing the tertiary structure of a polypeptide and selecting an exposed portion to modify or chemically modify may be done by, for example, comparing the sequence information of the polypeptide to be analyzed with a database storing the sequence information of known proteins, determining a template protein candidate based on the degree of sequence similarity, confirming the structure based on this, and selecting an exposed portion to modify or chemically modify, and modifying or modifying it.

[0126] The above 9) regulation of the intracellular location of a protein (polypeptide) may target the protein (polypeptide) to a specific organelle or specific intracellular space within the cell. For example, targeting to the periplasm or cytoplasm may be achieved by adding or removing a leader sequence that functions in targeting the protein (polypeptide), but is not limited thereto.

[0127] In one embodiment, the enhancement of the activity of the O-phosphoserine sulfhydrylase protein of the present application may be achieved by modifying the gene expression control region on the chromosome encoding the polypeptide of 2), by modifying the amino acid sequence or polynucleotide sequence of 4) and 5), or by a combination thereof.

[0128] In any one of the above-described embodiments, the activity enhancement of the O-phosphoserine sulfhydrylase protein of the present application may include an activity-enhanced gene expression regulatory sequence upstream of the cysM gene encoding it. For example, the gene expression regulatory sequence may be a promoter, but is not limited thereto. In another of the above-described embodiments, the activity enhancement of the O-phosphoserine sulfhydrylase protein of the present application may be by modifying the amino acid sequence of the O-phosphoserine sulfhydrylase protein or the polynucleotide sequence encoding it. The modification of the amino acid sequence or the polynucleotide sequence may include all of deletion, substitution, insertion, etc. The modification in the sequence is as described above.

[0129] Such enhancement of polypeptide activity may be, but is not limited to, an increase in the activity or concentration or expression level of the corresponding polypeptide relative to the activity or concentration of the polypeptide expressed in the wild type or pre-transformed microbial strain, or an increase in the amount of a product produced from the polypeptide.

[0130]

[0131] In the microorganism of the present application, modification of part or all of the polynucleotide may be induced by, but is not limited to, (a) homologous recombination using a vector for chromosome insertion into the microorganism or genome editing using engineered nucleases (e.g., CRISPR-Cas9) and / or (b) treatment with light and / or chemicals such as ultraviolet rays and radiation. The method for modifying part or all of the gene may include a method using DNA recombination technology. For example, a nucleotide sequence or vector containing a nucleotide sequence homologous to a target gene may be injected into the microorganism to cause homologous recombination, thereby causing deletion of part or all of the gene. The injected nucleotide sequence or vector may include, but is not limited to, a dominant selection marker.

[0132]

[0133] In this application, the term "attenuation" of the activity of a polypeptide (including, for example, proteins specified by the name of each enzyme) includes both a decrease in activity or absence of activity compared to the intrinsic activity. The term "attenuation" may be used interchangeably with terms such as inactivation, deficiency, down-regulation, decrease, reduce, and attenuation.

[0134] The above weakening may also include cases where the activity of the polypeptide itself is reduced or eliminated compared to the activity of the polypeptide originally possessed by the microorganism due to mutation of the polynucleotide encoding the polypeptide, etc., cases where the overall polypeptide activity level and / or concentration (expression amount) within the cell is lower than that of the natural strain due to inhibition of expression of the gene of the polynucleotide encoding the polypeptide or inhibition of translation into a polypeptide, cases where the polynucleotide is not expressed at all, and / or cases where the polypeptide has no activity even if the polynucleotide is expressed. The fact that the activity of the polypeptide is “inactivated, deficient, reduced, downregulated, reduced, attenuated” compared to the intrinsic activity means that the activity of a specific polypeptide originally possessed by the parent strain or unmodified microorganism before the transformation is lowered.

[0135] Attenuation of the activity of such polypeptides can be accomplished by any method known in the art, including but not limited to, and can be achieved by application of various methods well known in the art (e.g., Nakashima N et al., Bacterial cellular engineering by genome editing and gene silencing. Int J Mol Sci. 2014;15(2):2773-2793, Sambrook et al. Molecular Cloning 2012, etc.).

[0136]

[0137] Specifically, the weakening of the activity of the polypeptide of the present application is

[0138] 1) Deletion of all or part of a gene encoding a polypeptide;

[0139] 2) Modification of the expression control region (or expression control sequence) so as to reduce the expression of the gene encoding the polypeptide;

[0140] 3) Modification of the amino acid sequence constituting the polypeptide (e.g., deletion / substitution / addition of one or more amino acids in the amino acid sequence) so as to eliminate or weaken the activity of the polypeptide;

[0141] 4) Modification of the gene sequence encoding the polypeptide such that the activity of the polypeptide is eliminated or weakened (e.g., deletion / substitution / addition of one or more nucleotide bases in the nucleotide sequence of the polypeptide gene such that the polypeptide is modified such that the activity of the polypeptide is eliminated or weakened);

[0142] 5) Modification of the base sequence encoding the initiation codon or 5'-UTR region of a gene transcript encoding a polypeptide;

[0143] 6) Introduction of an antisense oligonucleotide (e.g., antisense RNA) that complementarily binds to a transcript of the gene encoding the polypeptide;

[0144] 7) Addition of a sequence complementary to the Shine-Dalgarno sequence in front of the Shine-Dalgarno sequence of a gene encoding a polypeptide to form a secondary structure to which ribosome attachment is impossible;

[0145] 8) Addition of a promoter that is transcribed in the opposite direction to the 3' end of the ORF (open reading frame) of the gene sequence encoding the polypeptide (Reverse transcription engineering, RTE);

[0146] 9) Control of cellular localization of proteins (polypeptides); or

[0147] 10) It may be a combination of two or more selected from 1) to 9), but is not particularly limited thereto.

[0148] for example,

[0149] The above 1) deletion of part or all of the gene encoding the polypeptide may be the removal of the entire polynucleotide encoding the endogenous target polypeptide in the chromosome, replacement with a polynucleotide having some nucleotides deleted, or replacement with a marker gene.

[0150] In addition, the above 2) modification of the expression control region (or expression control sequence) may be a mutation in the expression control region (or expression control sequence) by deletion, insertion, non-conservative or conservative substitution, or a combination thereof, or replacement with a sequence having weaker activity. The expression control region includes, but is not limited to, a promoter, an operator sequence, a sequence encoding a ribosome binding site, and a sequence regulating the termination of transcription and translation.

[0151] The modification of the amino acid sequence or polynucleotide sequence of the above 3) and 4) may be, but is not limited to, a mutation in the sequence of the amino acid sequence of the polypeptide or the polynucleotide sequence encoding the polypeptide, such as deletion, insertion, non-conservative or conservative substitution, or a combination thereof, so as to weaken the activity of the polypeptide, or replacement with an amino acid sequence or polynucleotide sequence improved to have weaker activity, or an amino acid sequence or polynucleotide sequence improved to have no activity. For example, the expression of the gene may be inhibited or weakened by introducing a mutation in the polynucleotide sequence to form a stop codon, but is not limited thereto.

[0152] The above 5) modification of the base sequence encoding the initiation codon or 5'-UTR region of the gene transcript encoding the polypeptide may be, for example, a substitution with a base sequence encoding another initiation codon having a lower polypeptide expression rate than the endogenous initiation codon, but is not limited thereto.

[0153] The introduction of an antisense oligonucleotide (e.g., antisense RNA) that complementarily binds to the transcript of the gene encoding the polypeptide 6) above can be described, for example, with reference to the literature [Weintraub, H. et al., Antisense-RNA as a molecular tool for genetic analysis, Reviews - Trends in Genetics, Vol. 1(1) 1986].

[0154] 7) Addition of a sequence complementary to the Shine-Dalgarno sequence in front of the Shine-Dalgarno sequence of a gene encoding a polypeptide to form a secondary structure to which ribosome attachment is impossible may render mRNA translation impossible or slow it down.

[0155] In addition, the addition of a promoter transcribed in the opposite direction to the 3' end of the ORF (open reading frame) of the gene sequence encoding the polypeptide (Reverse transcription engineering, RTE) may weaken the activity by creating an antisense nucleotide complementary to the transcript of the gene encoding the polypeptide.

[0156] The above 9) regulation of the intracellular location of a protein (polypeptide) may target the protein (polypeptide) to a specific organelle or specific intracellular space within the cell. For example, targeting to the periplasm or cytoplasm may be achieved by adding or removing a leader sequence that functions in targeting the protein (polypeptide), but is not limited thereto.

[0157] Such attenuation of polypeptide activity may include, but is not limited to, a decrease in the activity or concentration or expression level of the corresponding polypeptide relative to the activity or concentration of the polypeptide expressed in the wild type or pre-transformed microbial strain, or a decrease in the amount of a product produced from the polypeptide.

[0158]

[0159] In the microorganism of the present application, the O-phosphoserine sulfhydrylase variant, polynucleotide, and cysteine, etc. are as described in the other aspects above.

[0160]

[0161] Another aspect of the present application provides a method for producing cysteine ​​and derivatives thereof, comprising the step of reacting a mixture of O-phosphoserine and sulfide with an O-phosphoserine sulfhydrylase variant of the present application.

[0162] The method for producing cysteine ​​and its derivatives of the present application may include a step of culturing a microorganism comprising the O-phosphoserine sulfhydrylase variant of the present application or the polynucleotide of the present application or the vector of the present application in a medium prior to the method.

[0163] In this application, the term "cultivation" refers to growing the microorganism of this application under appropriately controlled environmental conditions. The culturing process of this application can be performed using any suitable medium and culture conditions known in the art. This culturing process can be easily adjusted and used by those skilled in the art depending on the selected microorganism. Specifically, the culturing process may be batch, continuous, and / or fed-batch, but is not limited thereto.

[0164] In this application, the term "medium" refers to a material containing nutrients as a main component necessary for culturing the microorganism of this application, and supplies nutrients and growth factors, including water, which is essential for survival and growth. Specifically, the medium and other culture conditions used for culturing the microorganism of this application may be any medium used for culturing general microorganisms without particular limitation, but the microorganism of this application may be cultured under aerobic conditions while controlling temperature, pH, etc. in a general medium containing an appropriate carbon source, nitrogen source, phosphorus source, inorganic compound, amino acid, and / or vitamin.

[0165] In the present application, the carbon source may include carbohydrates such as glucose, saccharose, lactose, fructose, sucrose, maltose, etc.; sugar alcohols such as mannitol, sorbitol, etc.; organic acids such as pyruvic acid, lactic acid, citric acid, etc.; amino acids such as glutamic acid, methionine, lysine, etc. In addition, natural organic nutrients such as starch hydrolysate, molasses, blackstrap molasses, rice winter, cassava, sugarcane bagasse, and corn steep liquor may be used, and specifically, carbohydrates such as glucose and sterilized pretreated molasses (i.e., molasses converted to reducing sugar) may be used, and other appropriate amounts of carbon sources may be used in various ways without limitation. These carbon sources may be used alone or in combination of two or more, but are not limited thereto.

[0166] The nitrogen source may include inorganic nitrogen sources such as ammonia, ammonium sulfate, ammonium chloride, ammonium acetate, ammonium phosphate, ammonium carbonate, ammonium nitrate, etc.; organic nitrogen sources such as amino acids such as glutamic acid, methionine, glutamine, etc.; peptone, NZ-amine, meat extract, yeast extract, malt extract, corn steep liquor, casein hydrolysate, fish or its decomposition product, defatted soybean cake or its decomposition product, etc. These nitrogen sources may be used alone or in combination of two or more, but are not limited thereto.

[0167] The above-mentioned components may include potassium phosphate monobasic, potassium phosphate dibasic, or their corresponding sodium-containing salts. Inorganic compounds may include sodium chloride, calcium chloride, iron chloride, magnesium sulfate, iron sulfate, manganese sulfate, calcium carbonate, etc. In addition, amino acids, vitamins, and / or suitable precursors may be included. These components or precursors may be added to the medium in batch or continuous manner, but are not limited thereto.

[0168] In addition, during the cultivation of the microorganism of the present application, compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, sulfuric acid, etc. may be added to the medium in an appropriate manner to adjust the pH of the medium. In addition, during the cultivation, foaming may be suppressed by using an antifoaming agent such as fatty acid polyglycol ester. In addition, in order to maintain the aerobic state of the medium, oxygen or an oxygen-containing gas may be injected into the medium, or in order to maintain the anaerobic and microaerobic state, nitrogen, hydrogen, or carbon dioxide gas may be injected without gas injection, but is not limited thereto.

[0169] In the culture of the present application, the culture temperature can be maintained at 20 to 45°C, specifically 25 to 40°C, and the culture can be performed for about 10 to 160 hours, but is not limited thereto.

[0170] The O-phosphoserine sulfhydrylase variant produced by the culture of the present invention can remain within the cell.

[0171]

[0172] The method for producing cysteine ​​of the present application may additionally include a step of preparing a microorganism of the present application, a step of preparing a medium for culturing the microorganism, or a combination thereof (in any order), for example, prior to the culturing step.

[0173] The cysteine ​​production method of the present application may additionally include a step of recovering an O-phosphoserine sulfhydrylase variant from a medium according to the above-described culture (a medium in which culture is performed) or from a microorganism of the present application.

[0174] The above recovery may be performed by collecting the desired mutant using a suitable method known in the art according to the culture method of the microorganism of the present application, such as a batch, continuous or fed-batch culture method. For example, various chromatographies such as centrifugation, filtration, treatment with a crystallized protein precipitant (salting out method), extraction, ultrasonic disruption, ultrafiltration, dialysis, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, affinity chromatography, HPLC or a combination thereof may be used, and the desired mutant may be recovered from the microorganism using a suitable method known in the art.

[0175] Additionally, a purification step may be included after the above-described recovery step. The purification may be performed using any suitable method known in the art. For example, when both a recovery step and a purification step are included, the recovery step and the purification step may be performed sequentially or discontinuously, regardless of order, or simultaneously or integrated into a single step, but this is not limited thereto.

[0176] In the method of the present application, the O-phosphoserine sulfhydrylase variant, polynucleotide, vector, strain, etc. are as described in the other embodiments above.

[0177]

[0178] The above sulfide may be used without limitation as long as it is a sulfide that can be converted into a thiol group (SH group) in the form of sulfide (S2-), thiosulfate (S2032-), etc., not only in a solid form commonly used in the relevant technical field, but also due to differences in pH, pressure, and solubility. Specifically, Na2S, NaSH, (NH4)2S, H2S, S2O3, or Na2S2O3 that provide a thiol group to OPS can be used, but is not limited thereto. The above reaction is a reaction that provides one thiol group to one OPS reactor to produce one cysteine ​​or a cysteine ​​derivative, and the amount of sulfide added during the reaction may be 0.1 to 3 times the molar concentration of OPS, specifically, may be 1 to 2 times, but is not limited thereto.

[0179] Additionally, the present application may further include a step of recovering cysteine ​​produced through the above reaction step. At this time, the desired cysteine ​​may be separated, purified, and collected from the reaction solution using a suitable reaction known in the art.

[0180]

[0181] In this application, the term "derivative" means a similar compound obtained by chemically changing a part of a compound, usually a compound in which a hydrogen atom or a specific atomic group in the compound is replaced by another atom or atomic group.

[0182] In this application, the term “cysteine ​​derivative” means a compound in which a hydrogen atom or a specific atomic group of cysteine ​​is replaced by another atom or atomic group. For example, it may be in the form where another atom or atomic group is attached to the nitrogen atom of the amine group (-NH 2) of cysteine ​​or the sulfur atom of the thiol group (-SH), and examples thereof include, but are not limited to, NAC (N-acetylcysteine), SCMC (S-Carboxymetylcysteine), BOC-CYS(ME)-OH, (R)-S-(2-Amino-2-carboxyethyl)-L-homocysteine, (R)-2-Amino-3-sulfopropionic acid, D-2-Amino-4-(ethylthio)butyric acid, 3-sulfino-L-alanine, Fmoc-Cys(Boc-methyl)-OH, Seleno-L-cystine, S-(2-Thiazolyl)-L-cysteine, S-(2-Thienyl)-L-cysteine, S-(4-Tolyl)-L-cysteine, etc.

[0183] If cysteine ​​is produced according to the method of the present application, conversion into cysteine ​​derivatives can be easily achieved by methods widely known in the art.

[0184]

[0185] In the present application, the method for producing a cysteine ​​derivative may additionally include a step of converting the cysteine ​​produced above into a cysteine ​​derivative.

[0186] Specifically, in the present application, the method for producing a cysteine ​​derivative may include a step of producing cysteine ​​according to the method of the present application described above; and a step of converting the produced cysteine ​​into a cysteine ​​derivative.

[0187] The conversion of the above-mentioned produced cysteine ​​into a cysteine ​​derivative can be performed by a method widely known in the art, for example, by reacting cysteine ​​with an acetylation agent in accordance with a method known in the art to synthesize NAC (N-acetylcysteine), or by reacting cysteine ​​with a haloacetic acid under basic conditions to synthesize SCMC (S-Carboxymetylcysteine), but is not limited thereto.

[0188] The above cysteine ​​derivatives can be used primarily as pharmaceutical raw materials, as antitussives, cough relievers, and as treatments for bronchitis, bronchial asthma, and pharyngitis, but are not limited thereto.

[0189]

[0190] Another aspect of the present application provides a composition for producing cysteine ​​or a derivative of cysteine, comprising the O-phosphoserine sulfhydrylase variant of the present application, a polynucleotide encoding the same, a vector comprising the polynucleotide, or a microorganism comprising the polynucleotide of the present application; a medium in which the same is cultured; or a combination of two or more thereof.

[0191] The composition of the present application may further comprise any suitable excipient commonly used in compositions for producing cysteine ​​or derivatives of cysteine, and such excipients may be, for example, but are not limited to, preservatives, wetting agents, dispersing agents, suspending agents, buffering agents, stabilizers, or isotonic agents.

[0192]

[0193] Another aspect of the present application provides a method for producing an O-phosphoserine-producing recombinant microorganism, comprising the step of introducing into the microorganism an O-phosphoserine sulfhydrylase variant of the present application; a polynucleotide of the present application; or a vector of the present application.

[0194]

[0195] Another aspect of the present application provides a use of the O-phosphoserine sulfhydrylase variant of the present application for producing cysteine ​​or a derivative of cysteine.

[0196]

[0197] Another aspect of the present application provides a use of an O-phosphoserine producing recombinant microorganism comprising an O-phosphoserine sulfhydrylase variant of the present application; a polynucleotide of the present application; or a vector of the present application for producing cysteine ​​or a derivative of cysteine.

[0198]

[0199] The O-phosphoserine sulfhydrylase variant, polynucleotide, vector, cysteine, derivative of cysteine ​​and microorganism of the above aspect are as described above.

[0200]

[0201] The present application will be described in more detail below through examples. However, the following examples are merely preferred embodiments intended to illustrate the present application and are therefore not intended to limit the scope of the present application. Furthermore, technical details not described herein can be readily understood and implemented by those skilled in the technical field of the present application or similar fields.

[0202]

[0203] Example 1: Screening of CysM mutants

[0204] A cysM gene mutant library encoding CysM mutants was constructed based on Msm-T-HA2 (US Patent No. US 9127324 B2) (SEQ ID NO: 11), a mutant in which 5 amino acid residues from the C-terminus of wild-type Mycobacterium smegmatics-derived CysM (Msm-OPSS) (SEQ ID NO: 1) are deleted and proline at the 77th amino acid residue from the N-terminus is substituted with serine, which exhibits O-phosphoserine (OPS) conversion activity to cysteine. Random mutagenesis was performed using an error-prone PCR kit (Diversity PCR random mutagenesis kit, Clontech).

[0205] Specifically, random mutagenesis PCR was performed using the base sequence encoding Msm-T-HA2 (SEQ ID NO: 12) as a template and the primer pair of SEQ ID NOs: 16 and 17. A diversity PCR random mutagenesis kit was used, and the PCR conditions were denaturation at 94°C for 5 minutes, followed by 20 cycles of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and polymerization at 72°C for 1 minute, followed by polymerization at 72°C for 5 minutes.

[0206] The amplified mutant gene fragments were each introduced into the pUC (Yanisch-Perron et al. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. 1985, Gene 33 (1), 103-119) vector (SEQ ID NO: 15) (pUC_PcysK) containing the cysK promoter. To construct the pUC_PcysK vector, first, PCR was performed using the primer pair of SEQ ID NO: 18 and 19 with E. coli ATCC27325 chromosomal DNA as a template to secure the cysK promoter fragment. The PCR conditions were denaturation at 94°C for 5 minutes, followed by 30 cycles of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and polymerization at 72°C for 1 minute, followed by polymerization at 72°C for 5 minutes. The amplified cysK promoter fragment was cloned into the pUC vector digested with restriction enzymes NheI and HindIII using an In-fusion cloning kit (Clontech Laboratories, Inc.) to construct the pUC_PcysK vector. The previously amplified mutant gene fragments were cloned into the pUC_PcysK vector digested with restriction enzyme EcoRV using an In-fusion cloning kit. Cloning was performed by reacting at 50°C for 60 minutes, and through this, the pUC_PcysK-cysM gene mutant plasmid library was constructed.

[0207] The primer sequences used here are as shown in Table 1 below.

[0208]

[0209] 서열번호서열명서열(5'->3')16cysM-mut-FAGTTAAGGAGATATCATGACGCGCTACGACTCCCTG17cysM-mut-RAGCCTTTCGTTTTATTTATTCCAGCGCGTCCTCGGC18PcysK-FTTACGCCAAGCTAGCCCAGCCTGTTTACGATGATC19PcysK-RGTCGTAGCGCGTCATGATATCTCCTTAACTGTATGA

[0210]

[0211] The above-constructed enzyme expression vector was transformed into Escherichia coli K12 strain by electroporation (Appl. Microbiol. Biotechnol. (1999) 52:541-545). Homologous recombination was induced on the chromosome (van der Rest et al., Appl Microbiol Biotechnol 52:541-545, 1999). Strains in which the vector was inserted into the chromosome by recombination of homologous sequences were selected on LB medium containing 25 mg / L kanamycin. DNA was obtained from three selected E. coli transformants using a DNA-spin plasmid DNA purification kit (Intron) according to the manufacturer's protocol, and the base sequence was analyzed using a sequencing technique. As a result of base sequence analysis, it was confirmed that the CysM mutants derived from three E. coli transformants each consist of the amino acid sequence of SEQ ID NO: 5, the amino acid sequence of SEQ ID NO: 7, and the amino acid sequence of SEQ ID NO: 9. In the case of the CysM mutant having the amino acid sequence of SEQ ID NO: 5, it was confirmed that the 77th amino acid residue, proline, was substituted with alanine in the amino acid sequence of the parental Mycobacterium smegmatis-derived CysM mutant, and that the 218th amino acid residue, alanine, was substituted with glycine. In the case of the CysM mutant having the amino acid sequence of SEQ ID NO: 7, it was confirmed that the 55th amino acid residue, alanine, was substituted with valine, the 77th amino acid residue, proline, was substituted with alanine, and the 218th amino acid residue, alanine, was substituted with glycine in the amino acid sequence of the parental Mycobacterium smegmatis-derived CysM mutant. In the case of the CysM mutant having an amino acid sequence of sequence number 9, it was confirmed that the 7th amino acid residue, leucine, was substituted with proline in the amino acid sequence of the parental sequence, the CysM mutant derived from Mycobacterium smegmatis, the 77th amino acid residue, proline, was substituted with alanine, and the 218th amino acid residue, alanine, was substituted with glycine.

[0212]

[0213] Example 2: Construction of CysM mutant expression vector and expression strain

[0214] 2-1. Construction of CysM mutant (P77A or P77S) expression vector and expression strain

[0215] To construct a strain expressing a CysM mutant containing only the mutation identified in Example 1 above, a CysM mutant expression vector was first constructed.

[0216] Specifically, to construct a CysM (P77A) expression vector, the base sequence (SEQ ID NO: 14) encoding Msm-T (US Patent No. 9,127,324 B2) (SEQ ID NO: 13), a mutant of wild-type Mycobacterium smegmatics-derived CysM (Msm-OPSS) with 5 amino acid residues deleted from the C-terminus, was used as a template to obtain an upper fragment of the cysM (P77A) gene through PCR using the primer pairs of SEQ ID NOs: 16 and 20, and a lower fragment of the cysM (P77A) gene was obtained through PCR using the primer pairs of SEQ ID NOs: 17 and 21 for the same template. To construct the CysM(P77S) (Msm-T-HA2) expression vector as a control, the cysM(P77S) gene fragment was obtained by PCR using Msm-T-HA2 as a template and the primer pair of SEQ ID NOs: 16 and 17. The PCR conditions were denaturation at 94°C for 5 minutes, followed by 30 cycles of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and polymerization at 72°C for 1 minute, followed by polymerization at 72°C for 5 minutes.

[0217] The above-obtained gene fragments were each introduced into a pUC vector (pUC_PcysK) containing the cysK promoter. The pUC_PcysK vector was prepared in Example 1. The previously obtained cysM (P77A) and cysM (P77S) gene fragments were cloned into the pUC_PcysK vector cut with the restriction enzyme EcoRV using an Infusion Cloning Kit. Cloning was performed by incubating at 50°C for 60 minutes.

[0218] The primer sequences used here are as shown in Table 2 below.

[0219]

[0220] SEQ ID NO Sequence Name Sequence (5'->3')16cysM-mut-FAGTTAAGGAGATATCATGACGCGCTACGACTCCCTG20P77A-ReverseGTGTTGCCGCTGGTGGCTTCCAGGATCGTG21P77A-ForwardCACGATCCTGGAAGCCACCAGCGGCAACAC

[0221]

[0222] Through this, pUC_PcysK-cysM(P77A) and pUC_PcysK-cysM(P77S) (Msm-T-HA2) vectors were obtained, respectively, and the vectors were transformed into E. coli K12 strain in the same manner as in Example 1 to secure a strain expressing CysM mutant (P77A or P77S).

[0223]

[0224] 2-2. Construction of CysM mutant (P77A / A218G) expression vector and expression strain

[0225] To construct a strain expressing a CysM mutant containing two combinations of mutations identified in Example 1 above, a CysM mutant expression vector was first constructed.

[0226] Specifically, to construct the cysM (P77A / A218G) expression vector, the upper fragment of the cysM (P77A / A218G) gene was obtained through PCR using the primer pair of SEQ ID NOs: 16 and 22 using cysM-4 (SEQ ID NO: 3) as a template, and the lower fragment of the cysM (P77A / A218G) gene was obtained through PCR using the primer pair of SEQ ID NOs: 17 and 23 for the same template. The PCR conditions were denaturation at 94°C for 5 minutes, followed by 30 cycles of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and polymerization at 72°C for 1 minute, followed by polymerization at 72°C for 5 minutes.

[0227] The primer sequences used here are as shown in Table 3 below.

[0228]

[0229] SEQ ID NO SEQUENCE NAME Sequence (5'->3')16cysM-mut-FAGTTAAGGAGATATCATGACGCGCTACGACTCCCTG17cysM-mut-RAGCCTTTCGTTTTATTTATTCCAGCGCGTCCTC GGC22A218G-RGCCCTCGTCGATGTTGCGCAGgcCGTACACGCCCTCGCCGTAACG23A218G-FCGTTACGGCGAGGGCGTGTACGgcCTGCGCAACATCGACGAGGGC

[0230]

[0231] The above-obtained gene fragments were cloned into the pUC_PcysK vector of Example 1, which was cut with the restriction enzyme EcoRV, using an infusion cloning kit. Cloning was performed by incubating at 50°C for 60 minutes. Through this, the pUC_PcysK-cysM (P77A / A218G) vector was obtained, and the vector was transformed into E. coli K12 strain using the same method as in Example 1 to secure a strain expressing the CysM mutant (P77A / A218G).

[0232]

[0233] Example 3. Evaluation of cysteine ​​conversion ability of strain expressing CysM mutants

[0234] 3-1. Evaluation of cysteine ​​conversion ability of strains expressing CysM mutants (P77A or P77S)

[0235] The pET system manual (novagen) was referenced for the method for enzyme expression. Specifically, a single colony of each strain of Example 2-1 was selected from a flat LB medium containing kanamycin, inoculated into 5 ml of LB liquid medium, and cultured for 16 hours at 37°C and 200 rpm. Next, the culture was inoculated into LB liquid medium containing kanamycin, and cultured for 18 hours at 33°C and 200 rpm. Xylene corresponding to 2% of the culture medium was added to the culture medium to obtain the enzyme. The enzyme obtained through the above process was individually confirmed through 14% SDS-PAGE (Fig. 1), and a soluble CysM (Msm-OPSS) mutant was obtained.

[0236] The enzyme activity of the soluble CysM mutants obtained above, K12 / pUC_Ppro-cysM(P77S) (Msm-T-HA2) and K12 / pUC_Ppro-cysM(P77A), converting OPS as a substrate into cysteine ​​was comparatively analyzed. The conditions for evaluating cysteine ​​synthesis activity (CysM enzyme assay) are as shown in Table 4 below.

[0237]

[0238] Stock sol'nFinal Conc.Volume10x his-enzyme 25 μL0.6M OPS in 1M Tris-HCl(pH 8.5)300mM500 μL1.5M Na2S-9H2O in D.W600mM380 μL10 mM PLP in D.W0.2mM20 μLD.W0.2mM75 μLTotal 1000 μL

[0239]

[0240] In Table 1, the remaining solutions excluding the enzyme were mixed and incubated at 37°C for 5 minutes, and then 25 μL of the xylene-treated soluble CysM variant was added and reacted at 37°C for 10 minutes. 100 μL of the completed reaction solution was taken and reacted with 900 μL of a mixture of 100 mM Tris-HCl (pH 8.5) and 10 mM DTT (dithiothreitol) for 30 minutes, and then the reaction was stopped using 0.1 M HCl. The concentration of cysteine ​​in the reaction solution was quantified through HPLC, and the cysteine ​​synthesis activity was evaluated by comparing the cysteine ​​conversion rate and specific activity (cysteine ​​concentration / time / enzyme amount) after 10 minutes of reaction, which are shown in Table 5 below.

[0241]

[0242] Strain name Specific activity (cysteine ​​(μmole) / min / mg) K12 / pUC_PcysK-cysM(P77S) (Msm-T-HA2) 12.6 K12 / pUC_PcysK-cysM(P77A) 18.4

[0243]

[0244] As shown in the results in Table 5 above, the cysM(P77A) expressing strain showed a 46% increase in specific activity compared to the control strain, cysM(P77S) (Msm-T-HA2), indicating improved cysteine ​​synthesis activity.

[0245]

[0246] 3-2. Evaluation of cysteine ​​conversion ability of strains expressing CysM mutant (P77A / A218G)

[0247] The enzyme activity for converting OPS as a substrate into cysteine ​​was compared and analyzed using K12 / pUC_PcysK-cysM (P77A / A218G), a soluble CysM mutant obtained by the method of Example 2-2. The experiment was performed in the same manner as in Example 3-1. The concentration of cysteine ​​in the reaction solution was quantified through HPLC, and the cysteine ​​conversion rate and specific activity (cysteine ​​concentration / time / enzyme amount) after 10 minutes of reaction were compared to evaluate the cysteine ​​synthesis activity, which is shown in Table 6 below.

[0248]

[0249] Strain name Specific activity (cysteine ​​(μmole) / min / mg) K12 / pUC_PcysK-cysM(P77A) 18.2 K12 / pUC_PcysK-cysM(P77A / A218G) 43.5

[0250]

[0251] As shown in the results in Table 6 above, the cysM (P77A / A218G) expressing strain showed a 13% increase in specific activity compared to the control strain, the cysM (P77A) expressing strain, indicating improved cysteine ​​synthesis activity.

[0252]

[0253] 3-3. Evaluation of cysteine ​​conversion ability of strains expressing CysM mutants (L7P / P77A / A218G or A55V / P77A / A218G)

[0254] The enzyme activity of CysM mutants K12 / pUC_PcysK-cysM(P77A / A218G), K12 / pUC_PcysK-cysM(L7P / P77A / A218G), and K12 / pUC_PcysK-cysM(A55V / P77A / A218G), which were obtained through screening from the library produced as a result of Example 1, was comparatively analyzed for converting OPS as a substrate into cysteine. The experiment was performed in the same manner as in Example 3-1. The concentration of cysteine ​​in the reaction solution was quantified through HPLC, and the cysteine ​​conversion rate and specific activity (cysteine ​​concentration / time / enzyme amount) after 10 minutes of reaction were compared to evaluate the cysteine ​​synthesis activity, which is shown in Table 7 below.

[0255]

[0256] Strain NameSpecific activity(cysteine(μmole) / min / mg)K12 / pUC_PcysK-cysM(P77A / A218G)44.3K12 / pUC_PcysK-cysM(L7P / P77A / A218G)62.8K12 / pUC_PcysK-cysM(A55V / P77A / A218G)76.4

[0257]

[0258] As shown in the results in Table 7 above, the cysM(L7P / P77A / A218G) expressing strain and the cysM(A55V / P77A / A218G) expressing strain showed improved cysteine ​​synthesis activity, with specific activities increasing by 41% and 72.5%, respectively, compared to the control strain, the cysM(P77A / A218G) expressing strain.

[0259] From the above description, those skilled in the art will understand that the present application can be implemented in other specific forms without altering its technical concept or essential characteristics. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of this application should be interpreted to include all changes or modifications derived from the meaning and scope of the following claims and their equivalents, rather than the detailed description above.

Claims

1. An O-phosphoserine sulfhydrylase mutant in which 0 to 7 amino acid residues from the C-terminus of the amino acid sequence of sequence number 1 are deleted and the amino acid corresponding to position 77 is substituted with alanine.

2. In the first paragraph, the O-phosphoserine sulfhydrylase variant is a variant in which 5 amino acid residues are deleted from the C-terminus in the amino acid sequence of SEQ ID NO:

1.

3. A variant according to claim 1, wherein the O-phosphoserine sulfhydrylase variant has a sequence identity or homology of 80% or more with sequence number 1.

4. In the first paragraph, the O-phosphoserine sulfhydrylase variant is a variant having an amino acid sequence of sequence number 3.

5. In the first paragraph, the O-phosphoserine sulfhydrylase variant is a variant in which an amino acid corresponding to a position selected from the group consisting of the 7th, 55th, 218th, and combinations thereof in the amino acid sequence of SEQ ID NO: 1 is substituted with another amino acid.

6. A variant in claim 5, wherein the amino acid corresponding to the 7th position in the amino acid sequence of sequence number 1 is substituted with proline.

7. A variant in claim 5, wherein the amino acid corresponding to the 55th position in the amino acid sequence of sequence number 1 is substituted with valine.

8. A variant in claim 5, wherein the amino acid corresponding to position 218 in the amino acid sequence of sequence number 1 is substituted with glycine.

9. In the fifth paragraph, the O-phosphoserine sulfhydrylase variant is a variant comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 7, and 9.

10. A polynucleotide encoding an O-phosphoserine sulfhydrylase variant of any one of claims 1 to 9.

11. A microorganism comprising an O-phosphoserine sulfhydrylase variant of any one of claims 1 to 9; or a polynucleotide encoding the same.

12. In claim 11, the microorganism has increased cysteine ​​production ability compared to a microorganism comprising a wild-type O-phosphoserine sulfhydrylase having the amino acid sequence of sequence number 1 or a polynucleotide encoding the same.

13. A microorganism according to claim 12, wherein the microorganism is a microorganism of the genus Escherichia.

14. A microorganism according to claim 13, wherein the Escherichia genus microorganism is Escherichia coli.

15. A method for producing cysteine ​​or a derivative thereof, comprising the step of adding an O-phosphoserine sulfhydrylase variant of any one of claims 1 to 9 to a mixture of O-phosphoserine and sulfide and reacting the same.

16. A method according to claim 15, wherein the O-phosphoserine is purified O-phosphoserine or a microbial fermentation solution containing O-phosphoserine.

17. A method according to claim 15, wherein the sulfide is at least one selected from the group consisting of Na2S, NaSH, (NH4)2S, H2S, S2O3, and Na2S2O3.

18. Use for producing cysteine ​​or a derivative thereof of an O-phosphoserine sulfhydrylase variant in which 0 to 7 amino acid residues from the C-terminus in the amino acid sequence of SEQ ID NO: 1 are deleted and the amino acid corresponding to position 77 is replaced with alanine.

19. Use of a microorganism for producing cysteine ​​or a derivative thereof, comprising an O-phosphoserine sulfhydrylase variant of any one of claims 1 to 9; a polynucleotide encoding the same; or a vector comprising the polynucleotide.

Citation Information

Patent Citations

  • Microorganisms and process for the fermentative production of L-Cystein, L-Cystin, N-Acetyl-Serin or thiazolidin-derivates

    EP0885962B1

  • O-phosphoserine sulfhydrylase mutants and method for production of cysteine using the same

    EP2444486B1

  • Promoter and uses thereof

    US10273491B2

  • Promoter and use thereof

    US10584338B2

  • Promoter sequences from Corynebacterium ammoniagenes

    US7662943B2